US 11,851,485 B2
Engineered anti-IL-2 antibodies
Inbar Amit, Modiin (IL); Itay Levin, Herzeliya (IL); Guy Nimrod, Tel Aviv (IL); Sharon Fischman, Modi'in (IL); Reut Barak Fuchs, Rehovot (IL); Marek Strajbl, Jerusalem (IL); Timothy Wyant, Bellingham, MA (US); Michael Zhenin, Jerusalem (IL); Olga Bluvshtein Yermolaev, Rishon-LeZion (IL); Yehezkel Sasson, Tzur Yigal (IL); Noam Grossman, Mazkeret Batyia (IL); Natalia Levitin, Ashdod (IL); and Yanay Ofran, Tel Aviv (IL)
Assigned to AULOS BIOSCIENCE, INC., Larkspur, CA (US)
Filed by Aulos Bioscience, Inc, Larkspur, CA (US)
Filed on Nov. 16, 2022, as Appl. No. 18/055,975.
Application 18/055,975 is a continuation of application No. 17/795,960, previously published as PCT/IB2021/051267, filed on Feb. 15, 2021.
Claims priority of provisional application 63/139,315, filed on Jan. 20, 2021.
Claims priority of provisional application 62/977,292, filed on Feb. 16, 2020.
Prior Publication US 2023/0203152 A1, Jun. 29, 2023
Int. Cl. C07K 16/24 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/246 (2013.01) [A61K 39/395 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 27 Claims
 
1. An isolated anti-IL-2 antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein said VH comprises heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2 and HCDR3, said VL comprises light chain complementarity determining regions (LCDRs) LCDR1, LCDR2 and LCDR3, wherein said CDRs have the amino acid sequences of
(a) the HCDR1 comprises the amino acid sequence of SEQ ID NO:62, the HCDR2 comprises the amino acid sequence of SEQ ID NO:63, the HCDR3 comprises the amino acid sequence of SEQ ID NO:64, the LCDR1 comprises the amino acid sequence of SEQ ID NO:65, the LCDR2 comprises the amino acid sequence DAS, the LCDR3 comprises the amino acid sequence of SEQ ID NO:67;
(b) the HCDR1 comprises the amino acid sequence of SEQ ID NO:38, the HCDR2 comprises the amino acid sequence of SEQ ID NO:39, the HCDR3 comprises the amino acid sequence of SEQ ID NO:40, the LCDR1 comprises the amino acid sequence of SEQ ID NO:41, the LCDR2 comprises the amino acid sequence YAS, the LCDR3 comprises the amino acid sequence of SEQ ID NO:43;
(c) the HCDR1 comprises the amino acid sequence of SEQ ID NO:44, the HCDR2 comprises the amino acid sequence of SEQ ID NO:45, the HCDR3 comprises the amino acid sequence of SEQ ID NO:46, the LCDR1 comprises the amino acid sequence of SEQ ID NO:47, the LCDR2 comprises the amino acid sequence YAS, the LCDR3 comprises the amino acid sequence of SEQ ID NO:49;
(d) the HCDR1 comprises the amino acid sequence of SEQ ID NO:50, the HCDR2 comprises the amino acid sequence of SEQ ID NO:51, the HCDR3 comprises the amino acid sequence of SEQ ID NO:52, the LCDR1 comprises the amino acid sequence of SEQ ID NO:53, the LCDR2 comprises the amino acid sequence YAS, the LCDR3 comprises the amino acid sequence of SEQ ID NO:55; or
(e) the HCDR1 comprises the amino acid sequence of SEQ ID NO:56, the HCDR2 comprises the amino acid sequence of SEQ ID NO:57, the HCDR3 comprises the amino acid sequence of SEQ ID NO:58, the LCDR1 comprises the amino acid sequence of SEQ ID NO:59, the LCDR2 comprises the amino acid sequence YAS, the LCDR3 comprises the amino acid sequence of SEQ ID NO:61.